LANNETT COMPANY,INC. (NYSE:LCI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders
At the Annual Meeting of Stockholders (the Annual Meeting) of
Lannett Company,Inc. (the Company) held on January18, 2017, two
proposals were voted on by the Companys stockholders. The
proposals are described in detail in the Companys definitive
proxy statement filed on December12, 2016 in connection with the
Annual Meeting. A brief description of the proposals and the
final results of the votes for these matters are as follows:
1. The stockholders elected all six director nominees to serve as
members of the Companys board of directors until the Companys
next Annual Meeting of Stockholders and until their respective
successors have been duly elected and qualified.
The number of votes cast for or withheld, for each nominee, was
as follows:
|
|
VotesFor |
|
VotesWithheld |
|
|
|
Jeffrey Farber |
25,193,886 |
1,010,851 |
|||
|
Arthur P. Bedrosian |
25,818,523 |
386,214 |
|||
|
David Drabik |
19,359,064 |
6,845,673 |
|||
|
Paul Taveira |
19,369,901 |
6,834,836 |
|||
|
Jim Maher |
19,372,943 |
6,831,794 |
|||
|
Albert Paonessa,III |
19,381,561 |
6,823,176 |
2. The stockholders ratified the appointment of Grant Thornton,
LLP as independent auditors. The number of votes cast for,
against, or abstained was as follows:
Votes For: 32,843,608
Votes Against: 110,216
Abstain: 70,002
About LANNETT COMPANY, INC. (NYSE:LCI)
Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms. LANNETT COMPANY, INC. (NYSE:LCI) Recent Trading Information
LANNETT COMPANY, INC. (NYSE:LCI) closed its last trading session down -0.40 at 19.20 with 1,202,531 shares trading hands.
